Table 1.
Immunogenicity of M-M-R II in individuals 6–11 months and ≥7 years of age
| Author, Year | Study Country (Study period) | Population, N receiving M-M-R II | Age | Time frame post-vaccination | Immunogenicity | ||
|---|---|---|---|---|---|---|---|
| |
|
|
|
|
Measles |
Mumps |
Rubella |
| 6–11 months of age | |||||||
| Redd13 | US (1992–1994) | 285 | 9.6 months (mean) | 1 month | 87.4% SCR defined as detectable antibody post-vaccination but not pre-vaccination (indirect EIA) | 92.3% SCR defined as detectable antibody post-vaccination but not pre-vaccination (indirect EIA) | 91.2% SCR defined as detectable antibody post-vaccination but not pre-vaccination (indirect EIA) |
| ≥7 years of age | |||||||
| Abu-Elyazeed20 | US, Estonia and Slovakia (2014–2015) | 457, with at least one previous dose of a MMR vaccine | 25.6 years (mean) | 42 days | 99.1% SRR defined as ≥200 mIU/mL (ELISA) | 99.5% SRR defined as ≥10 EU/mL (ELISA) | 99.8% SRR defined as ≥10 IU/mL (ELISA) |
| Gothefors18 | Sweden (1997) | 150, who had a first dose of M-M-R II in their 2nd year | 11–12 years (range) | 40 days | 5.7% immune response defined as ≥4-fold increase in pre-vaccination antibody activity in initially seropositive subjects (ELISA) | 24.1% immune response defined as ≥4-fold increase in pre-vaccination antibody activity in initially seropositive subjects | 39.7% immune response defined as ≥4-fold increase in pre-vaccination antibody activity in initially seropositive subjects |
| 100% SCR defined as appearance of detectable antibody activity in initially seronegative subjects (ELISA) | 100% SCR defined as appearance of detectable antibody activity in initially seronegative subjects | 100% SCR defined as appearance of detectable antibody activity in initially seronegative subjects | |||||
| Diaz-Ortega15 | Mexico (2010–2011) | 62 (M-M-R II via injection) All received one dose of a M-M-R II at 1–2 years |
6.72 (mean) | 1 month | 100% SCR defined as ≥120 mIU/mL (PRN) | 100% SCR defined as ≥500 U/mL (ELISA) | 100% SCR ≥10 IU/mL (ELISA) |
| 1 year | 100% | 90.3% | 100% | ||||
| Diaz-Ortega16 | Mexico | 100 (not specified if prevaccinated or unvaccinated) | 18–25 years (range enrolled) | 2 months | 96% SCR defined as ≥120 mIU/mL (PRN) |
65%* SCR defined as ≥100 U/mL (ELISA) |
100% SCR defined as ≥10 IU/mL (ELISA) |
| 1 year | 95% | 38%* | 100% | ||||
| Sarno17 | Mexico (1999–2000) | 40 (standard syringe); 12/40 had received prior measles vaccine, 1/40 MMR at 12 months of age |
11.1 years (mean) | 12 weeks | 100% above baseline | 95% above baseline | 97.5% above baseline |
| Dos Santos14 | Brazil (1996) | 219, previously vaccinated and unvaccinated | 8.92 years (mean) | 21–30 days | 99.5% SPR, threshold not defined (ELISA) |
94.5% SPR, threshold not defined (ELISA) |
91.3% SPR, threshold not defined (ELISA) |
| Cassidy19** | US (1996–1997) | 97 (all vaccines at visit 1), 100 (HB at visit 1, Td and M-M-R II at 4.5 months) [dose 2] | 11–12 years (range) | 6 weeks | 100% [HB, M-M-R II and Td at visit 1] 100% [HB at visit 1, M-M-R II and Td at 4.5 months] SP defined as ≥120 IU/ml (EIA) |
100% [HB, M-M-R II and Td at visit 1] 100% [HB at visit 1, M-M-R II and Td at 4.5 months] SP defined as >1.0 IU/ml (EIA) |
100% [HB, M-M-R II and Td at visit 1] 100% [HB at visit 1, M-M-R II and Td at 4.5 months] SP defined as >0.10 IU/ml (EIA) |
EIA: Enzyme Immunoassay; ELISA: Enzyme-linked immunosorbent assay; HB: Hepatitis B; NR: Not reported; PRN: Plaque reduction neutralization; SCR: Seroconversion rate; SPR: Seropositivity rate; SP: seroprotection; SRR: seroresponse rate; Td: Tetanus-diphtheria
*Authors noted that the mumps antibody levels obtained with the present tests may not accurately reflect actual immunity.
**All other antigens also 100% in both groups with the exception of 98.8% for tetanus and diphtheria in the group receiving HB at visit 1 while M-M-R II and Td at visit 4.5 months.